stoxline Quote Chart Rank Option Currency Glossary
  
ERYTECH Pharma S.A. (ERYP)
0.78  0.01 (1.3%)    06-28 15:48
Open: 0.8195
High: 0.84
Volume: 3,205
  
Pre. Close: 0.77
Low: 0.78
Market Cap: 47(M)
Technical analysis
2023-09-01 4:46:52 PM
Short term     
Mid term     
Targets 6-month :  0.7 1-year :  0.85
Resists First :  0.6 Second :  0.73
Pivot price 0.52
Supports First :  0.39 Second :  0.32
MAs MA(5) :  0.53 MA(20) :  0.55
MA(100) :  0.79 MA(250) :  0.73
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  44.6 D(3) :  46.8
RSI RSI(14): 45
52-week High :  1.39 Low :  0.3
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ERYP ] has closed below upper band by 40.7%. Bollinger Bands are 31.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.54 - 0.54 0.54 - 0.55
Low: 0.48 - 0.48 0.48 - 0.48
Close: 0.53 - 0.54 0.54 - 0.54
Company Description

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.

Headline News

Tue, 13 Jun 2023
Erytech's Battle With Activist Investor Echoes As Pherecydes Pharma Merger Vote Comes Closer - Yahoo Finance

Tue, 23 May 2023
ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes - Yahoo Finance

Tue, 09 May 2023
ERYTECH Provides Business and Financial Update for the First Quarter of 2023 - Yahoo Finance

Tue, 26 Apr 2022
Healthcare Stocks Moving Tuesday: COSM, MORF, QIPT, VVOS, PTGX, PHAS, ERYP, VLON - InvestorsObserver

Mon, 25 Apr 2022
ERYTECH Sells U.S. Manufacturing Facility and Enters - GlobeNewswire

Fri, 08 Apr 2022
Erytech Pharma SA (ERYP) Stock Falls -20.00% This Week; Should You Buy? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.1
EBITDA (p.s.) -0.42
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 4.92
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android